| Cognitive impairment in multiple sclerosis: diagnosis and monitoring V Meca-Lallana, F Gascón-Giménez, RC Ginestal-López, Y Higueras, ... Neurological Sciences 42 (12), 5183-5193, 2021 | 73 | 2021 |
| Combined cerebrospinal fluid neurofilament light chain protein and chitinase-3 like-1 levels in defining disease course and prognosis in multiple sclerosis S Gil-Perotin, J Castillo-Villalba, L CUBAS-NÚÑEZ, R Gasqué, DH Marin, ... Frontiers in Neurology 10, 1008, 2019 | 62 | 2019 |
| Optimal management of severe nausea and vomiting in migraine: improving patient outcomes MJA Láinez, A García-Casado, F Gascón Patient related outcome measures 4, 61, 2013 | 59 | 2013 |
| Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study C Alcalá, F Gascón, F Pérez-Miralles, S Gil-Perotin, A Navarre, I Bosca, ... Journal of neurology 265 (7), 1690-1697, 2018 | 54 | 2018 |
| Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis B Casanova, I Jarque, F Gascón, JC Hernández-Boluda, F Pérez-Miralles, ... Neurological Sciences 38 (7), 1213-1221, 2017 | 54 | 2017 |
| Effect of ocrelizumab in blood leukocytes of patients with primary progressive MS JI Fernández-Velasco, J Kuhle, E Monreal, V Meca-Lallana, ... Neurology-Neuroimmunology Neuroinflammation 8 (2), 2021 | 51 | 2021 |
| Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies F Coret, FC Pérez-Miralles, F Gascón, C Alcalá, A Navarré, A Bernad, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 4 (2 …, 2018 | 45 | 2018 |
| Sphenopalatine ganglion stimulation for the treatment of cluster headache MJA Láinez, M Puche, A Garcia, F Gascón Therapeutic advances in neurological disorders 7 (3), 162-168, 2014 | 31 | 2014 |
| CSF chitinase 3-like-1 association with disability of primary progressive MS F Pérez-Miralles, D Prefasi, A García-Merino, F Gascón-Giménez, ... Neurology-Neuroimmunology Neuroinflammation 7 (5), 2020 | 29 | 2020 |
| Escalation vs. Early Intense Therapy in Multiple Sclerosis B Casanova, C Quintanilla-Bordás, F Gascón Journal of Personalized Medicine 12 (1), 119, 2022 | 27 | 2022 |
| Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe C Alcalá, F Gascón, F Pérez-Miralles, JA Domínguez, S Gil-Perotín, ... Journal of neurology 266 (3), 726-734, 2019 | 27 | 2019 |
| Perception of stigma in patients with primary progressive multiple sclerosis F Pérez-Miralles, D Prefasi, A García-Merino, JR Ara, G Izquierdo, ... Multiple Sclerosis Journal–Experimental, Translational and Clinical 5 (2 …, 2019 | 20 | 2019 |
| Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: a secondary autoimmune disease C Alcalá, F Pzére-Miralles, F Gascón, M Evole, M Estutia, S Gil-Perotín, ... Multiple sclerosis and related disorders 27, 406-408, 2019 | 18 | 2019 |
| Therapeutic plasma exchange: applications in neurology JM Lainez-Andres, F Gascon-Gimenez, F Coret-Ferrer, ... Revista de neurologia 60 (3), 120-131, 2015 | 17 | 2015 |
| Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study C Alcalá, C Quintanilla-Bordás, F Gascón, ÁP Sempere, L Navarro, ... Journal of Neurology, 1-6, 2022 | 14 | 2022 |
| Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study) F Pérez-Miralles, D Prefasi, A García-Merino, JR Ara, G Izquierdo, ... Multiple sclerosis and related disorders 50, 102860, 2021 | 14 | 2021 |
| Exacerbation of relapses following mRNA COVID-19 vaccination in multiple sclerosis: a case series C Quintanilla-Bordás, F Gascon-Gimenez, CA Vicente, M Payá Montes, ... Frontiers in Neurology, 780, 0 | 14 | |
| Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients B Casanova, L Lacruz, ML Villar, JA Domínguez, MC Gadea, F Gascón, ... Neurological Sciences 39 (8), 1423-1430, 2018 | 11 | 2018 |
| Recambio plasmático terapéutico: aplicaciones en Neurología JM Láinez-Andrés, F Gascón-Giménez, F Coret-Ferrer, ... Rev Neurol 60 (3), 120-31, 2015 | 8 | 2015 |
| Treatment of multiple sclerosis with Teriflunomide. Multicenter study of real clinical practice in the Valencian Community-Spain LL Pascual, FC Pérez-Miralles, SG Gil-Perotin, A Belenguer, F Gascón, ... Frontiers in Neurology, 1920, 0 | 8 | |
